Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P01861
UPID:
IGHG4_HUMAN
Alternative names:
Ig gamma-4 chain C region
Alternative UPACC:
P01861; A0A286YFJ8
Background:
Immunoglobulin heavy constant gamma 4 (Ig gamma-4 chain C region) plays a pivotal role in the immune response. It is a component of immunoglobulins, or antibodies, which are produced by B lymphocytes. These antibodies can be either membrane-bound or secreted and are essential for the recognition and elimination of antigens. The antigen binding site of each immunoglobulin is highly specific, formed by the variable domains of one heavy and one light chain, allowing precise targeting of antigens.
Therapeutic significance:
Understanding the role of Immunoglobulin heavy constant gamma 4 could open doors to potential therapeutic strategies. Its critical function in the immune response highlights its potential as a target for therapeutic intervention in immune-related diseases.